Dynamic Metabolic Control (DMC) Biotechnologies, a U.S.-based biotechnology company, has received $34 million in the Series B funding round. Top investors include Solvay Ventures, Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures and Michelin.
DMC Biotechnologies creates scalable biocatalysts through microbial fermentation, resulting in bio-based chemicals for animal feed, human nutrition, sustainable cleaning and pharmaceutical applications.
The core technology is considered the next innovation in the biotechnology paradigm for its high yields and predictability for scale-up operations.
Thomas Canova, R&D portfolio management and technology scouting director for Solvay and head of Solvay Ventures, says, “DMC has demonstrated exceptional speed by moving from targeted molecules to products ready for commercialization at the right scale. The versatility of the platform, translated into the large range of products, aligns perfectly with Solvay's aspiration to bring more bio-based solutions to market.”